Troiano G, et al. revealed that CD68+ TAMs had no prognostic utility in patients with squamous cell carcinoma of the head and neck, however CD163+ TAMs predicted poor prognosis [39]. This evidence concerns the gene CD163 and squamous cell carcinoma.